CDC Panel Extends Johnson & Johnson Vaccine Pause Amid Blood Clot Probe
A CDC advisory committee keeps the Johnson & Johnson Covid-19 vaccine on hold while experts gather more data on rare but severe blood clot risks. The panel plans to reconvene in a week to make a final recommendation.
An independent advisory panel to the Centers for Disease Control and Prevention declines to lift the pause on the Johnson & Johnson Covid-19 vaccine. Committee members state they need more time to investigate rare but severe blood clot reports linked to the shot. Because the Pfizer and Moderna vaccines remain widely available without these specific safety concerns, the panel decides to wait for additional data.
Experts emphasize that the blood clot risk appears very low, but they do not yet know exactly how rare it is or how to best treat the specific condition. Most panel members agree that the pause should not last indefinitely and express a strong desire to reconvene within one to two weeks. Dr. Beth Bell notes that fully understanding this low risk is crucial before resuming the vaccine's distribution.
Despite the extended pause, some committee members voice concern about the ongoing public health crisis, noting that new Covid-19 cases hold steady at over 60,000 per day. Dr. Grace Lee highlights the urgent race against time and emerging variants, stressing that officials must act quickly but in the safest possible way. The committee ultimately balances the need to protect the public from severe side effects with the need to maintain vaccination momentum.